Evenity (Romosozumab) and PPIs (Omeprazole, Pantoprazole): Interaction Guide

Romosozumab (Evenity), a sclerostin-inhibiting monoclonal antibody given as a monthly subcutaneous injection for postmenopausal osteoporosis with high fracture risk, has no known pharmacokinetic interaction with proton pump inhibitors (PPIs) such as omeprazole or pantoprazole. Romosozumab is cleared by intracellular proteolytic degradation, not by cytochrome P450 enzymes, transporters, or renal filtration, so a PPI cannot raise or lower its blood levels. The clinically relevant question is not whether the two drugs interact directly, it is whether long-term PPI use undermines the bone-building effect that romosozumab is meant to produce, through impaired calcium absorption and an independently elevated fracture risk associated with chronic acid suppression. That pharmacodynamic concern is real but is based on observational and mechanistic evidence, not on a trial that tested romosozumab specifically in PPI users.

This is a source-audit revision of an earlier draft. Several statistics in the original version (exact percentages, sample sizes, and journal citations) could not be verified against the specific papers linked, so those numbers have been removed or narrowed below and flagged for editorial verification rather than presented as established facts.

What Romosozumab Is and How It's Cleared

Romosozumab is a humanized IgG2 monoclonal antibody that binds sclerostin, a protein made by osteocytes that normally suppresses bone formation through the Wnt signaling pathway. Blocking sclerostin increases bone formation and, to a lesser degree, decreases bone resorption. It is FDA-approved for postmenopausal women with osteoporosis at high fracture risk, given as two 105 mg subcutaneous injections once monthly for a maximum of 12 doses (12 months). It carries a boxed warning for cardiovascular risk (myocardial infarction, stroke) and should not be started in patients with a myocardial infarction or stroke in the preceding year; verify current wording against the FDA-approved Evenity label before prescribing, since label language can be updated after initial approval.

Like other therapeutic monoclonal antibodies, romosozumab is broken down by proteolytic enzymes throughout the body rather than metabolized by liver enzymes. This is the pharmacologic reason PPIs, which act mainly through gastric acid suppression and hepatic CYP2C19/CYP3A4 effects, have no mechanism by which to change romosozumab exposure.

Why PPIs Don't Change Romosozumab Levels

Omeprazole, pantoprazole, and related PPIs irreversibly inhibit the H+/K+-ATPase pump on gastric parietal cells. Their known interaction mechanisms involve altering gastric pH (affecting absorption of pH-dependent oral drugs), CYP2C19/CYP3A4 inhibition, and, for some drugs, changes in renal tubular handling. None of these mechanisms touches a subcutaneously injected antibody that is cleared by proteolysis. Consult a current interaction database (Lexicomp, Micromedex, or the FDA label directly) before assuming this applies to every new PPI or biologic combination, since interaction databases are updated over time and this article reflects the mechanism, not a real-time database lookup.

The Real Concern: Long-Term PPI Use and Bone Health

Romosozumab's benefit depends on adequate calcium and vitamin D status and on a bone-remodeling environment that isn't already working against it. Chronic PPI use is independently associated with two effects relevant to that goal, both established well before romosozumab existed.

Reduced calcium absorption. Gastric acid helps dissolve and ionize calcium carbonate, the most commonly used over-the-counter calcium salt. Acid suppression from a PPI has been shown in small controlled studies to meaningfully reduce absorption from calcium carbonate specifically, while calcium citrate, which does not require an acidic environment to dissolve, is largely unaffected. The magnitude reported in the source material for this reduction could not be independently confirmed here and should be verified against the primary study before it is quoted as a fixed percentage.

Increased fracture risk with long-term use. The FDA added a warning about possible increased risk of hip, wrist, and spine fractures with long-term or high-dose PPI use to prescription and over-the-counter PPI labels in 2010; that warning is a regulatory fact, distinct from the pooled effect sizes from later observational meta-analyses. Multiple observational cohorts and meta-analyses published after that warning have reported increased fracture risk with PPI use of a year or longer, though estimates vary by study design, population, and how "long-term" is defined. Because these are observational associations, not randomized trial results, they cannot establish that PPIs cause fractures independent of the conditions (frailty, malabsorption, polypharmacy) that lead a patient to be prescribed a PPI long-term in the first place. Cite the specific effect size only after checking the source paper; do not treat a number pulled from a secondary summary as authoritative.

Magnesium and downstream vitamin D effects. The FDA has also documented cases of symptomatic hypomagnesemia associated with prolonged PPI use, sometimes after months of therapy, requiring magnesium repletion or PPI discontinuation. Low magnesium can impair parathyroid hormone secretion and vitamin D activation, which compounds a calcium deficit. Romosozumab itself has been associated with transient decreases in serum calcium; verify the current reported frequency in the FDA label rather than relying on a specific percentage from a secondary source, since exact incidence figures should come from the label or the primary trial publication.

The combination of an antibody that transiently pulls calcium into new bone, plus a medication that reduces calcium absorption and may independently raise fracture risk, is a plausible mechanism for reduced treatment benefit. It has not been tested directly: neither of romosozumab's two pivotal trials (commonly known by their trial names FRAME and ARCH) published a pre-specified subgroup analysis by baseline PPI use, so there's no trial-level evidence quantifying how much a PPI blunts romosozumab's effect in practice.

What the Pivotal Romosozumab Trials Do and Don't Tell Us

Romosozumab's approval rested on two large randomized trials in postmenopausal women with osteoporosis, generally described in the literature as producing substantial gains in lumbar spine bone mineral density over 12 months and reduced new vertebral fractures compared with control arms (placebo in one trial, alendronate in the other, followed by a switch to an antiresorptive agent in both). The second trial also generated the cardiovascular safety signal that led to the boxed warning. Exact percentages for BMD change and fracture reduction are well established in the trial publications but are not reproduced here as specific numbers because they should be sourced from the primary papers directly rather than from a secondary summary; an editor with journal access should confirm and cite the exact figures from the original New England Journal of Medicine reports before publication.

Neither trial's public reporting broke out efficacy or adverse events by concomitant PPI use. This means clinical guidance for co-prescribing has to be extrapolated from what is known about PPIs and bone health generally, not from direct trial evidence about this specific combination. That gap is the central uncertainty on this page.

Evidence Boundary: What Is Established vs. Plausible vs. Unknown

Established: Romosozumab has no cytochrome P450, P-glycoprotein, or renal-transporter-mediated interaction with PPIs; its clearance mechanism (proteolytic degradation) doesn't overlap with how PPIs affect other drugs. The FDA has warned since 2010 that long-term or high-dose PPI use may be associated with increased fracture risk. PPIs reduce the acid-dependent dissolution of calcium carbonate; calcium citrate absorption does not depend on gastric acid.

Plausible but unproven: That co-prescribing a PPI during a 12-month romosozumab course meaningfully reduces the BMD gain or fracture-risk reduction romosozumab would otherwise produce. This follows logically from the separate mechanisms above but has not been measured in a trial or subgroup analysis specific to romosozumab.

Not established: Any specific quantitative estimate of how much smaller the romosozumab benefit is in PPI users versus non-users. No published subgroup data exist to support a number, and none should be quoted as though it does.

Requires verification before clinical use: Any specific percentage figures for PPI-associated fracture risk increase, calcium carbonate absorption reduction, or romosozumab-associated hypocalcemia incidence that appear in secondary summaries (including earlier versions of this page). Pull these from the FDA label or the original trial or cohort publication before citing them to a patient or in clinical documentation.

A Practical Framework for Assessing This Combination

Practical Points for Co-Prescribing

No dose adjustment of romosozumab or the PPI is pharmacokinetically required. The steps below are pharmacodynamic risk-mitigation, not corrections to a verified drug interaction, and should be individualized rather than applied as a fixed protocol:

• Confirm the reason for the PPI. Patients on a PPI for uncomplicated reflux or empiric symptom control are reasonable candidates for a step-down conversation (lower dose, on-demand use, or a trial of an H2-receptor antagonist) in consultation with the prescribing clinician. Patients with Barrett esophagus, a history of bleeding ulcer, or other indications for continued full-dose acid suppression generally should not step down solely to accommodate romosozumab therapy.
• If the PPI continues, consider calcium citrate rather than calcium carbonate, since its absorption doesn't depend on stomach acid.
• Correct hypocalcemia and check vitamin D status before starting romosozumab, per the FDA label requirement, and monitor calcium and magnesium during the treatment course based on clinical judgment.
• At the end of the 12-month romosozumab course, when transitioning to an antiresorptive agent, revisit PPI use again, particularly if the plan is an oral bisphosphonate rather than denosumab.

When to Seek Urgent Care

Symptoms of significant hypocalcemia (muscle cramps, spasms, numbness or tingling around the mouth or in the extremities, seizures) or symptoms of a cardiovascular event (chest pain, sudden weakness, slurred speech, given romosozumab's boxed warning) require urgent medical evaluation rather than waiting for a scheduled follow-up. These are reasons to contact a clinician promptly regardless of PPI status.

Bottom Line

There is no drug-drug interaction to manage between romosozumab and PPIs in the pharmacokinetic sense. There is a legitimate, mechanism-based reason to reassess PPI necessity, supplement form, and mineral status in a patient starting a 12-month romosozumab course, because PPIs and romosozumab both touch calcium and bone metabolism through separate pathways. What is missing is direct trial evidence quantifying that interaction in romosozumab users specifically, and any clinical communication about this combination should say so rather than implying a level of precision the evidence doesn't support.

References

• U.S. Food and Drug Administration. Evenity (romosozumab-aqqg) prescribing information (label, initial approval 2019). https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761062s000lbl.pdf, verify against current label version at time of use.
• U.S. Food and Drug Administration. Omeprazole prescribing information, including fracture-risk warning language. https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/019810s096lbl.pdf, verify against current label version at time of use.
• U.S. Food and Drug Administration. Prolia (denosumab) prescribing information, for post-romosozumab sequencing discussion; consult the current FDA label directly, as the previously linked version could not be verified.
• Endocrine Society. Clinical practice guideline resources on osteoporosis management. https://www.endocrine.org/clinical-practice-guidelines/osteoporosis